Frailty and sarcopenia in fibrosing ILDs: what it means for prognosis and care
Official title: Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact
Run by Nantes University Hospital · NCT07004595 · Data updated 2026-11-12
This study tests how frailty and muscle loss together affect outcomes in people aged 65 and older with fibrosing interstitial lung diseases who are treated in outpatient settings.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 1 site (Nantes, Nantes) |
| Status | Recruiting |
| Started | July 20, 2025 |
| Main results expected | February 20, 2026 |
| Study ends | December 20, 2027 |
| Registry record updated | June 24, 2026 |
| Trial ID | NCT07004595 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are French-speaking adults 65 or older with fibrosing ILD (per ATS/ERS/JRS/ALAT 2022 criteria) seen in outpatient clinics at Nantes, who can complete questionnaires and provide informed consent.
✕Probably not a fit
Patients who do not present frailty or sarcopenia may have outcomes similar to other non-frail patients and may derive limited new information from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will evaluate frailty as a whole-patient risk factor in adults with fibrosing interstitial lung diseases. It aims to determine the prognostic impact of both frailty and sarcopenia, and their combined effect on outcomes, in an outpatient French population aged 65 and older. Data will come from assessments performed in routine clinic visits, focusing on how these conditions relate to treatment tolerance and survival. The study seeks to identify patients who may need tailored therapeutic decisions due to higher risk from frailty and muscle loss. Results could inform clinical practice by highlighting the potential value of routine frailty and sarcopenia screening in fibrosing ILDs.
Why it matters
Potential benefit: If successful, the study could help clinicians better predict who may have poorer outcomes or tolerate antifibrotic therapy less well, enabling more personalized care.
How similar studies have gone: Prognostic importance of frailty and sarcopenia has been studied separately in aging and lung disease, but the combined impact in fibrosing ILDs is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with fibrosing ILD according to the ATS/ERS/JRS/ALAT 2022 criteria. * Patient aged ≥ 65 years. * Outpatient consultation (scheduled appointment in an outpatient clinic, day hospital, or weekly hospital stay). * French-speaking patient. * Patient who has received an information sheet explaining the study and has not expressed opposition to participating in this research. Exclusion Criteria: * Patient under legal guardianship, curatorship, or judicial protection. * Cognitive disorders limiting the use of questionnaires. * Patient with a CT scan showing an early usual interstitial pneumonia (UIP) pattern according to the ATS/ERS/JRS/ALAT 2022 classification.
Where it's running
-
CHU Nantes - Respiratory Department
Nantes, Nantes, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
-
Bone marrow mesenchymal stem cell injection for sarcopenia
This study tests whether CG-BM1, a stem cell injection, can be safely given to adults with sarcopenia to see if it helps improve muscle health.
-
GLP-1 receptor agonist use and muscle health in adults with obesity without diabetes
This study tests whether GLP-1 receptor agonists affect muscle mass and strength in adults with obesity who don’t have diabetes.
-
Sarcopenia and Epidural Steroid Injections in Lumbar Spinal Stenosis
We’re testing how sarcopenia relates to pain, function, and quality of life after a routine interlaminar epidural steroid injection in people with lumbar spinal stenosis.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
-
Lower-limb rehabilitation robot training with nutrition education for sarcopenia
In adults aged 60 and older with sarcopenia, this study tests whether adding robot-assisted leg training to nutrition education can improve muscle mass and walking ability compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.